{"version":"1.0","provider_name":"Market Newsdesk","provider_url":"https:\/\/www.marketnewsdesk.com","author_name":"Newsdesk","author_url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/","title":"Savara Provides Pipeline and Business Update - Market Newsdesk","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"zYFJqM3KUY\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/savara-provides-pipeline-and-business-update\/\">Savara Provides Pipeline and Business Update<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.marketnewsdesk.com\/index.php\/savara-provides-pipeline-and-business-update\/embed\/#?secret=zYFJqM3KUY\" width=\"600\" height=\"338\" title=\"&#8220;Savara Provides Pipeline and Business Update&#8221; &#8212; Market Newsdesk\" data-secret=\"zYFJqM3KUY\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/www.marketnewsdesk.com\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","description":"Savara Provides Pipeline and Business Update Announces Phase 3 AVAIL Trial Missed Primary Endpoint, Stopping Further Development of AeroVanc Appoints Matt Pauls, Chairman and Interim CEO Since September 2020, Chairman and Permanent CEO Reduces Operating Expenses to Align with Streamlined Development Programs Discontinues Development of Apulmiq Program, Focuses Resources on Molgradex in aPAP Revises Study-Start Guidance for IMPALA 2 Clinical Trial to Q2 2021 AUSTIN, Texas&#8211;(BUSINESS WIRE)&#8211;Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today provided an update on changes to the Company\u2019s pipeline, leadership, and business operations that are being taken to improve alignment of resources and increase our focus on Molgradex in aPAP and the Phase 3 IMPALA 2 trial. \u201cI am grateful for the opportunity to &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005220r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"}